BRISTOL-MYERS SQUIBB COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 44.74 USD | +2.45% |
|
+2.38% | -12.80% |
| 09/05 | India's Alembic Pharma posts higher Q4 profit on strong N.America sales | RE |
| 07/05 | Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 46.02B 3,840B | Sales 2025 * | 46.16B 3,851B | Capitalization | 88.52B 7,385B |
|---|---|---|---|---|---|
| Net income 2024 * | -5.4B -451B | Net income 2025 * | 10.22B 853B | EV / Sales 2024 * | 2.78 x |
| Net Debt 2024 * | 39.2B 3,271B | Net Debt 2025 * | 31.85B 2,657B | EV / Sales 2025 * | 2.61 x |
| P/E ratio 2024 * |
-16.6
x | P/E ratio 2025 * |
8.25
x | Employees | 34,100 |
| Yield 2024 * |
5.51% | Yield 2025 * |
5.79% | Free-Float | 69.28% |
More Fundamentals
* Assessed data
More news
Latest transcript on Bristol-Myers Squibb Company
More recommendations
More press releases
More news
| 1 day | +2.45% | ||
| 1 week | +2.38% | ||
| Current month | +1.82% | ||
| 1 month | -13.29% | ||
| 3 months | -10.18% | ||
| 6 months | -11.25% | ||
| Current year | -12.80% |
1 week
43.50
44.81
1 month
43.3351.29
Current year
43.3355.04
1 year
43.3369.10
3 years
43.3381.44
5 years
42.4881.44
10 years
42.4881.44
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 53 | 01/15/01 | |
David Elkins
DFI | Director of Finance/CFO | 55 | 20/19/20 |
Greg Meyers
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Phyllis Yale
BRD | Director/Board Member | 66 | 20/19/20 |
Peter Arduini
BRD | Director/Board Member | 59 | 01/16/01 |
Derica Rice
BRD | Director/Board Member | 59 | 01/20/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 12.97% | 0 M€ | +11.39% | - | |
| 4.99% | 2 M€ | -.--% | ||
| 4.01% | 0 M€ | +5.54% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 08/24/08 | 43.67 | -0.84% | 11,928,339 |
| 07/24/07 | 44.04 | +0.32% | 11,026,912 |
| 06/24/06 | 43.9 | -0.20% | 9,127,651 |
| 03/24/03 | 43.99 | +0.66% | 12,104,489 |
| 02/24/02 | 43.7 | -1.15% | 15,962,587 |
Delayed Quote Nyse, May 10, 2024 at 01:30 am IST
More quotes
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
HOLD
Number of Analysts
25
Last Close Price
43.67
USD
Average target price
53.19
USD
Spread / Average Target
+21.81%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -12.80% | 88.52B | |
| +32.36% | 698B | |
| +26.51% | 568B | |
| -4.40% | 358B | |
| +19.46% | 328B | |
| +3.50% | 283B | |
| +16.34% | 238B | |
| +6.68% | 203B | |
| -9.08% | 198B | |
| +8.62% | 165B |
- Stock Market
- Equities
- BMY Stock